Combined targeting of EGFR and BRAF triggers regression of osimertinib resistance by using osimertinib and vemurafenib concurrently in a patient with heterogeneity between different lesions

Combined targeting of EGFR and BRAF triggers regression of osimertinib resistance by using osimertinib and vemurafenib concurrently in a patient with heterogeneity between different lesions

Abstract Acquired BRAF V600E mutation can occur in tumors with EGFR mutation and is suspected as a resistance mechanism to third‐generation EGFR‐tyrosine kinase inhibitors (TKIs). However, the treatment strategy for the coexistence of EGFR and acquired BRAF mutation with heterogeneity in lung cancer...

Full description

Bibliographic Details
Main Authors: Mengyao Sun, Xu Wang, Yinghui Xu, Chao Sun, Ye Guo, Shi Qiu, Renshan Zhao, Wenhao Zhu, Kewei Ma
Format: Article
Language:English
Published: Wiley 2022-02-01
Series:Thoracic Cancer
Subjects:
acquired BRAF mutation
EGFR mutation
heterogeneity
osimertinib
vemurafenib
Online Access:https://doi.org/10.1111/1759-7714.14295

Similar Items

Similar Items